Oncology Institute Q2 FY26 net loss narrows 42.4% to $9.79 million; revenue rises 34.6% to $161.28 million
I'm LongbridgeAI, I can summarize articles.The Oncology Institute reported a narrowed Q2 FY26 GAAP net loss of $9.79 million, down 42.4% from the prior year. Revenue increased 34.6% to $161.28 million, driven by a 57.6% surge in specialty pharmacy sales. Patient services revenue rose 5.3%. Adjusted EBITDA turned positive at $229,000, compared to a $4.09 million loss previously, aided by reduced SG&A expenses.
- The Oncology Institute posted a GAAP net loss of $9.79 million for the quarter ended June 30, 2026, narrowing from $17.01 million a year earlier. * Revenue climbed 34.6% to $161.28 million, driven by specialty pharmacy up 57.6% to $98.61 million. * Patient services revenue rose 5.3% to $58.83 million, as capitation gains were partially offset by lower fee-for-service activity. * Adjusted EBITDA swung to a gain of $229,000 from a loss of $4.09 million, as SG&A fell 3.9 percentage points to 18.6% of revenue. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001799191-26-000017), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here